NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/13/2022
Back to search
Official data from USPTO
MOLECULAR THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
MOLECULAR THERAPY
ST13
US500000090455037Class
9, 16, 41
Filing
90455037
Registration
6920629
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
12/13/2022
Classification
Registered
Trademark type
Word
Nice classes
9, 16, 41
Filing date
01/08/2021
Registration date
12/13/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/13/2022
Last transaction
12/13/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
01/31/2000
First use in commerce
01/31/2000
Drawing code
4
Owner type
03
Owner location
Waukesha, WI, US
Examiner
MARSH,BRANDON N
Law office
T10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
The American Society of Gene & Cell Therapy
Representatives
Patrick M Bergin VON BRIESEN & ROPER, S.C.
Technical classification
Nice Classes
Class 9Class 16Class 41
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Downloadable journals in the field of gene transfervector development and designstem cell manipulationdevelopment of gene-basedpeptide-basedprotein-basedoligonucleotide-basedcell-based therapeutics to correct genetic and acquired diseases
Class 16
Printed journals in the field of gene transfervector development and designstem cell manipulationdevelopment of gene-basedpeptide-basedprotein-basedoligonucleotide-basedcell-based therapeutics to correct genetic and acquired diseases
Class 41
Providing online non-downloadable journals in the field of gene transfervector development and designstem cell manipulationdevelopment of gene-basedpeptide-basedprotein-basedoligonucleotide-basedcell-based therapeutics to correct genetic and acquired diseases
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/13/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/27/2022
PUBO
PUBLISHED FOR OPPOSITION
09/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/23/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/25/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/25/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/25/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/24/2021
GNRT
NON-FINAL ACTION E-MAILED
04/24/2021
CNRT
NON-FINAL ACTION WRITTEN
04/24/2021
DOCK
ASSIGNED TO EXAMINER
04/22/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/07/2021
NWAP
NEW APPLICATION ENTERED
01/12/2021
Continuous trademark protection
Get notified about every new filing that threatens MOLECULAR THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.